The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial
Abstract
OBJECTIVE: To analyze the frequency, clinical characteristics, and predictors of symptomatic intracerebral hemorrhage (ICH) after intraarterial (IA) thrombolysis with recombinant pro-urokinase (r-proUK) in acute ischemic stroke. METHOD: The authors conducted an exploratory analysis of symptomatic ICH from a randomized, controlled clinical trial of IA thrombolysis with r-proUK for patients with angiographically documented occlusion of the middle cerebral artery within 6 hours from stroke onset. Patients (n = 180) were randomized in a ratio of 2:1 to either 9 mg IA r-proUK over 120 minutes plus IV fixed-dose heparin or IV fixed-dose heparin alone. As opposed to intention to treat, this analysis was based on "treatment received" and includes 110 patients given r-proUK and 64 who did not receive any thrombolytic agent. The remaining six patients received out-of-protocol urokinase and were excluded from analysis. The authors analyzed centrally adjudicated ICH with associated neurologic deterioration (increase in NIH Stroke Scale [NIHSS] score of > or =4 points) within 36 hours of treatment initiation. RESULTS: Symptomatic ICH occurred in 12 of 110 patients (10.9%) treated with r-proUK and in two of 64 (3.1%) receiving heparin alone. ICH symptoms in r-proUK-treated patients occurred at a mean of 10.2 +/- 7.4 hours after the start of treatment. Mortality after symptomatic ICH was 83% (10/12 patients). Only blood glucose was significantly associated with symptomatic ICH in r-proUK-treated patients based on univariate analyses of 24 variables: patients with baseline glucose >200 mg/dL experienced a 36% risk of symptomatic ICH compared with 9% for those with < or =200 mg/dL (p = 0.022; relative risk, 4.2; 95% CI, 1.04 to 11.7). CONCLUSIONS: Symptomatic ICH after IA thrombolysis with r-proUK for acute ischemic stroke occurs early after treatment and has high mortality. The risk of symptomatic ICH may be increased in patients with a blood glucose >200 mg/dL at stroke onset.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)08020-9 · Cited by 3,662
Furlan, A., Higashida, R., Wechsler, L., Gent, M., Rowley, H., Kase, C., Pessin, M., Ahuja, A., Callahan, F., Clark, W. M., et al. (1999) · JAMA · doi:10.1001/jama.282.21.2003 · Cited by 3,073
Self-citationdel Zoppo, G. J., Higashida, R. T., Furlan, A. J., Pessin, M. S., Rowley, H. A., & Gent, M. (1998) · Stroke · doi:10.1161/01.str.29.1.4 · Cited by 1,239
Self-citationClark, W. M., Wissman, S., Albers, G. W., Jhamandas, J. H., Madden, K. P., Hamilton, S., & for the ATLANTIS Study Investigators (1999) · JAMA · doi:10.1001/jama.282.21.2019 · Cited by 1,186
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
del Zoppo, G. J., Poeck, K., Pessin, M. S., Wolpert, S. M., Furlan, A. J., Ferbert, A., Alberts, M. J., Zivin, J. A., Wechsler, L., Busse, O., et al. (1992) · Annals of Neurology · doi:10.1002/ana.410320113 · Cited by 999
Self-citationIntracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke
The NINDS t-PA Stroke Study Group (1997) · Stroke · doi:10.1161/01.str.28.11.2109 · Cited by 880
The arterial lesions underlying lacunes
Fisher, C. M. (1969) · Acta Neuropathologica · doi:10.1007/bf00685305 · Cited by 755
Albers, G. W., Bates, V. E., Clark, W. M., Bell, R., Verro, P., & Hamilton, S. A. (2000) · JAMA · doi:10.1001/jama.283.9.1145 · Cited by 700
Cited by
Higashida, R. T., & Furlan, A. J. (2003) · Stroke · doi:10.1161/01.str.0000082721.62796.09 · Cited by 1,543
Self-citationThrombolysis for acute ischaemic stroke
Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000213.pub3 · Cited by 1,370
Broderick, J., Connolly, S., Feldmann, E., Hanley, D., Kase, C., Krieger, D., Mayberg, M., Morgenstern, L., Ogilvy, C. S., Vespa, P., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.183689 · Cited by 1,125
Self-citationWarfarin, hematoma expansion, and outcome of intracerebral hemorrhage
Flibotte, J. J., Hagan, N., O’Donnell, J., Greenberg, S. M., & Rosand, J. (2004) · Neurology · doi:10.1212/01.wnl.0000138428.40673.83 · Cited by 632
Impact of medical complications on outcome after subarachnoid hemorrhage*
Wartenberg, K. E., Schmidt, J. M., Claassen, J., Temes, R. E., Frontera, J. A., Ostapkovich, N., Parra, A., Connolly, E. S., & Mayer, S. A. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000201903.46435.35 · Cited by 592
Metadata
- Authors
- Kase, C. S., Furlan, A. J., Wechsler, L. R., Higashida, R. T., Rowley, H. A., Hart, R. G., Molinari, G. F., Frederick, L. S., Roberts, H. C., Gebel, J. M., Sila, C. A., Schulz, G. A., Roberts, R. S., Gent, M., & the PROACT II Investigators
- Venue
- Neurology
- Published
- 2001-11-13
- Volume
- 57
- Issue
- 9
- Pages
- 1603-1610
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2042267799
- Cited by
- 332
- References
- 27
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial. https://app.cochat.ai/papers/10.1212/wnl.57.9.1603
- The paper
- Kase, C. S., Furlan, A. J., Wechsler, L. R., Higashida, R. T., Rowley, H. A., Hart, R. G., Molinari, G. F., Frederick, L. S., Roberts, H. C., Gebel, J. M., Sila, C. A., Schulz, G. A., Roberts, R. S., Gent, M., & the PROACT II Investigators. (2001). Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial. Neurology. https://doi.org/10.1212/wnl.57.9.1603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
